Position in HLN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$6,586,774
-$766,271 QoQ
Shares Held
705,978
-3.9% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#63
of 640 holders
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Callan Family Office, LLC holds $18,949,973 across 11 Drug Manufacturers - Specialty & Generic names. HLN ranks #1 (34.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
This page
|
705,978 | $6,586,774 | |
| 2 | ELAN |
Elanco Animal Health Inc
|
161,687 | $3,979,117 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
165,303 | $2,649,807 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
50,826 | $1,721,984 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
2,246 | $1,216,950 | |
| 6 | ZTS |
Zoetis Inc.
|
12,528 | $900,262 | |
| 7 | HIMS |
Hims & Hers Health, Inc.
|
17,702 | $613,728 | |
| 8 | PBH |
Prestige Consumer Healthcare Inc.
|
11,584 | $547,575 |
All Filings in HLN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,586,774 | 705,978 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $7,353,045 | 734,570 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $7,467,741 | 738,649 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $6,018,618 | 670,972 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $7,876,263 | 759,524 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $2,148,685 | 208,813 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $1,970,000 | 206,499 | Shares | Sole | 2025-02-07 | |
| 2023-03-31 | $341,066 | 41,900 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||